相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
D. Handolias et al.
BRITISH JOURNAL OF CANCER (2010)
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
Qing-Bai She et al.
CANCER CELL (2010)
Receptor Tyrosine Kinase Coactivation Networks in Cancer
Alexander M. Xu et al.
CANCER RESEARCH (2010)
IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence
Lyndee L. Scurr et al.
CELL (2010)
Role for IGFBP7 in Senescence Induction by BRAF
Narendra Wajapeyee et al.
CELL (2010)
A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
Alexander Roesch et al.
CELL (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Pratilas et al.
CLINICAL CANCER RESEARCH (2010)
Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: A new potential therapy for the treatment of melanoma
Thomas B. Karasic et al.
EXPERIMENTAL CELL RESEARCH (2010)
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
Janice M. Mehnert et al.
HUMAN PATHOLOGY (2010)
Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions
Michael D. Schaller
JOURNAL OF CELL SCIENCE (2010)
KIT as a Therapeutic Target in Melanoma
Maria C. Garrido et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors
Alfonso Zambon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Tie1-Tie2 Interactions Mediate Functional Differences between Angiopoietin Ligands
Tom C. M. Seegar et al.
MOLECULAR CELL (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
P. J. Mishra et al.
ONCOGENE (2010)
Nuclear trafficking of the epidermal growth factor receptor family membrane proteins
Y-N Wang et al.
ONCOGENE (2010)
ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma
Aline Primot et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
EphA2 as a promoter of melanoma tumorigenicity
Naira V. Margaryan et al.
CANCER BIOLOGY & THERAPY (2009)
EphA2 Reexpression Prompts Invasion of Melanoma Cells Shifting from Mesenchymal to Amoeboid-like Motility Style
Matteo Parri et al.
CANCER RESEARCH (2009)
The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function
Timothy A. Chan et al.
CELL CYCLE (2009)
Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
Nikolaus Schicher et al.
CLINICAL CANCER RESEARCH (2009)
Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors
Shao-Chun Wang et al.
CLINICAL CANCER RESEARCH (2009)
Tyrosine-phosphorylation: thirty years and counting
Tony Hunter
CURRENT OPINION IN CELL BIOLOGY (2009)
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas
Atsuko Ashida et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Ultraviolet Irradiation-Induces Epidermal Growth Factor Receptor (EGFR) Nuclear Translocation in Human Keratinocytes
Yiru Xu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Michael G. Gartside et al.
MOLECULAR CANCER RESEARCH (2009)
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Todd D. Prickett et al.
NATURE GENETICS (2009)
ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
Emelie A. Djerf et al.
MELANOMA RESEARCH (2009)
A genomic screen identifies TYRO3 as a MITF regulator in melanoma
Shoutian Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Platelet-Derived Growth Factor-Receptor α Strongly Inhibits Melanoma Growth In Vitro and In Vivo
Debora Faraone et al.
NEOPLASIA (2009)
Phase II trial of imatinib mesylate in patients with metastatic melanoma
K. B. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression
Keiran S. M. Smalley et al.
CANCER RESEARCH (2008)
EphA2 is an essential mediator of UV radiation-induced apoptosis
Guoqi Zhang et al.
CANCER RESEARCH (2008)
Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma
David A. Solomon et al.
CANCER RESEARCH (2008)
Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells
Jane Goodall et al.
CANCER RESEARCH (2008)
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7
Narendra Wajapeyee et al.
CELL (2008)
Eph-ephrin bidirectional signaling in physiology and disease
Elena B. Pasquale
CELL (2008)
PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic β-catenin and affects membrane distribution of β-catenin/E-cadherin complexes in cancer cells
Luisa Novellino et al.
CELLULAR SIGNALLING (2008)
HER3 is a determinant for poor prognosis in melanoma
Markus Reschke et al.
CLINICAL CANCER RESEARCH (2008)
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells
Ling-Yuan Kong et al.
CLINICAL CANCER RESEARCH (2008)
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2008)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Jeffrey A. Engelman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Receptor tyrosine kinases: the emerging tip of systems control
R. Seger et al.
IET SYSTEMS BIOLOGY (2008)
Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase
Wei Bin Fang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The current status and evolving role of sunitinib in non-small cell lung cancer
Mark A. Socinski
JOURNAL OF THORACIC ONCOLOGY (2008)
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
H. Korkaya et al.
ONCOGENE (2008)
Metastatic melanoma: Scientific rationale for sorafenib treatment and clinical results
Friederike Egberts et al.
ONKOLOGIE (2008)
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
Jose Lutzky et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Understanding signaling cascades in melanoma
Pablo Lopez-Bergami et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2008)
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib
Alfonso Quintas-Cardama et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
How to make a melanoma: what do we know of the primary clonal events?
Dorothy C. Bennett
PIGMENT CELL & MELANOMA RESEARCH (2008)
Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells
Niels Eckstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines
Jens E. Ruhe et al.
CANCER RESEARCH (2007)
Uncovering therapeutic targets for glioblastoma - A systems biology approach
Paul H. Huang et al.
CELL CYCLE (2007)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Antagonism of platelet-derived growth factor receptor in non-small cell lung cancer: Rationale and investigations
Julie E. Bauman et al.
CLINICAL CANCER RESEARCH (2007)
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
D. Mahadevan et al.
ONCOGENE (2007)
The tumor suppressor PP2A Aβ regulates the RaIA GTPase
Anna A. Sablina et al.
CELL (2007)
Binding of Ras to phosphoinositide 3-kinase p110α is required for Ras-driven tumorigenesis in mice
Surbhi Gupta et al.
CELL (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
c-Met is a potentially new therapeutic target for treatment of human melanoma
Neelu Puri et al.
CLINICAL CANCER RESEARCH (2007)
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays
Mitchell Stark et al.
CANCER RESEARCH (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Platelet-derived growth factor receptor-α is a key determinant of smooth muscle α-actin filaments in bone marrow-derived mesenchymal stem cells
Stephen G. Ball et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma
K. A. Giehl et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2007)
Protein tyrosine phosphatases: from genes, to function, to disease
Nicholas K. Tonks
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib
Floriana Morgillo et al.
CANCER RESEARCH (2006)
Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs
A. H. Yeh et al.
ONCOGENE (2006)
Oxidative inhibition of receptor-type protein-tyrosine phosphatase κ by ultraviolet irradiation activates epidermal growth factor receptor in human keratinocytes
Yiru Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
c-Met expression is regulated by Mitf in the melanocyte lineage
GG McGill et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Molecular targets in melanoma from angiogenesis to apoptosis
JA Sosman et al.
CLINICAL CANCER RESEARCH (2006)
Protein-tyrosine phosphatases and cancer
A Östman et al.
NATURE REVIEWS CANCER (2006)
MITF: master regulator of melanocyte development and melanoma oncogene
Carmit Levy et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Receptor-type protein-tyrosine phosphatase-κ regulates epidermal growth factor receptor function
YR Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
LA Garraway et al.
NATURE (2005)
Microarray analysis of phosphatase gene expression in human melanoma
L McArdle et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Lack of clinical efficacy of imatinib in metastatic melanoma
S Ugurel et al.
BRITISH JOURNAL OF CANCER (2005)
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells
A Thelemann et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
Tyrosine kinase receptors as attractive targets of cancer therapy
A Bennasroune et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2004)
Protein tyrosine phosphatases in the human genome
A Alonso et al.
CELL (2004)
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3
P George et al.
CANCER RESEARCH (2004)
Diverse roles of Eph receptors and ephrins in the regulation of cell migration and tissue assembly
A Poliakov et al.
DEVELOPMENTAL CELL (2004)
Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor
BE Peace et al.
EXPERIMENTAL CELL RESEARCH (2003)
Tyrosine phosphate in melanoma progression
L McArdle et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Identification of a mutated receptor-like protein tyrosine phosphatase κ as a novel, class IIHLA-restricted melanoma antigen
L Novellino et al.
JOURNAL OF IMMUNOLOGY (2003)
Molecular plasticity of human melanoma cells
MJC Hendrix et al.
ONCOGENE (2003)
Apoptosis and melanoma chemoresistance
MS Soengas et al.
ONCOGENE (2003)
Differential regulation of EphA2 in normal and malignant cells
J Walker-Daniels et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer
MS Kinch et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Receptor tyrosine kinases as rational targets for prostate cancer treatment: Platelet-derived growth factor receptor and imatinib mesylate
DJ George
UROLOGY (2002)
Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression
O Straume et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Protein tyrosine phosphatase genes downregulated in melanoma
L McArdle et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
Protein tyrosine kinases in malignant melanoma
DJ Easty et al.
MELANOMA RESEARCH (2000)
分享论文
